Pharmaceutical - Novo Nordisk

Filter

Current filters:

Novo Nordisk

Popular Filters

1 to 25 of 142 results

Novo Nordisk's Victoza granted label extension in the UK

Novo Nordisk's Victoza granted label extension in the UK

20-01-2015

A license extension has been granted in the UK for Victoza (liraglutide) from Danish insulin giant Novo…

Nephrology and HepatologyNovo NordiskPharmaceuticalRegulationUKVictoza

Novo Nordisk chooses Switzerland as first country to launch Xultophy

Novo Nordisk chooses Switzerland as first country to launch Xultophy

19-01-2015

Danish diabetes care giant Novo Nordisk has launched Xultophy (IDegLira) for people with type 2 diabetes…

DiabetesMarkets & MarketingNovo NordiskPharmaceuticalSwitzerlandXultophy

Novo Nordisk’s obesity drug Saxenda approved by FDA

Novo Nordisk’s obesity drug Saxenda approved by FDA

24-12-2014

Continuing its rush of year-end drug approvals, the US Food and Drug Administration late yesterday approved…

MetabolicsNovo NordiskPharmaceuticalRegulationSaxendaUSA

Erectile dysfunction and diabetes drugs to be tested as dementia treatments

Erectile dysfunction and diabetes drugs to be tested as dementia treatments

12-12-2014

The Alzheimer's Drug Discovery Foundation (ADDF) and the Alzheimer's Society UK announced new funding…

CialisDiabetesEli LillyliraglutideMen's HealthNeurologicalNovo NordiskPharmaceuticalResearchTadalafilVictoza

Positive new Ph III data for Novo Nordisk’s NovoEight in hemophilia A

08-12-2014

Danish diabetes major Novo Nordisk yesterday presented a new analysis of Phase III data demonstrating…

HematologyNovo NordiskNovoEightPharmaceuticalResearch

CHMP positive opinion on Victoza in type 2 diabetes patients with moderate renal impairment

CHMP positive opinion on Victoza in type 2 diabetes patients with moderate renal impairment

21-11-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive…

DiabetesEuropeNovo NordiskPharmaceuticalRegulationVictoza

Pharma companies can still improve access to medicines, report shows

Pharma companies can still improve access to medicines, report shows

17-11-2014

Top pharma companies are doing more to improve access to medicine in developing countries over the last…

GlaxoSmithKlineGlobalMarkets & MarketingNovo NordiskPharmaceuticalSanofi

New Phase IIIa data further demonstrate benefits of liraglutide in obesity

04-11-2014

Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchSaxendaVictoza

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

04-11-2014

A new study has suggested that drugs currently being used to treat diabetes also have the potential to…

liraglutidelixisenatideNeurologicalNovo NordiskPharmaceuticalResearchSanofiUK

aTyr Pharma appoints Fred Ramsdell as vice president of immunology

aTyr Pharma appoints Fred Ramsdell as vice president of immunology

03-11-2014

Rare disease specialist aTyr Pharma has appointed Fred Ramsdell as vice president of immunology.

aTyrBoardroomNovo NordiskPharmaceuticalUSA

Novo Nordisk and Roche Diabetes Care launch new treatment option

Novo Nordisk and Roche Diabetes Care launch new treatment option

03-11-2014

Danish diabetes care giant Novo Nordisk has today launched NovoRapid PumpCart, the first pre-filled pump…

DiabetesMarkets & MarketingNovo NordiskNovoRapidPharmaceuticalRocheSwitzerland

Novo Nordisk begins building $130 million lab facility in Denmark

Novo Nordisk begins building $130 million lab facility in Denmark

31-10-2014

Danish insulin giant Novo Nordisk has made a 750 million Danish kroner ($130 million) investment in new…

DenmarkDiabetesNovo NordiskPharmaceuticalProduction

Novo Nordisk posts strong results, reassures with guidance

Novo Nordisk posts strong results, reassures with guidance

30-10-2014

Global diabetes care giant, Denmark’s Novo Nordisk saw its shares gain 4% to 265.80 Danish kroner this…

DiabetesFinancialNovo NordiskPharmaceutical

Novo Nordisk subpoenaed by US Attorney

Novo Nordisk subpoenaed by US Attorney

25-10-2014

Danish diabetes care giant Novo Nordis on Friday revealed it had been served with a subpoena by the office…

DenmarkDiabetesLegalNovo NordiskPharmaceuticalProductionUSA

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

08-10-2014

Ultra-rapid formulations of the currently marketed rapid-acting insulin analogs have the clear potential…

AdociaBioChaperoneDiabetesFIAspGlobalMarkets & MarketingNovo NordiskPharmaceuticalResearch

Novo Nordisk establishes new obesity research unit in Seattle

Novo Nordisk establishes new obesity research unit in Seattle

26-09-2014

Danish diabetes care giant Novo Nordisk yesterday announced that the company will establish a new obesity…

ManagementMetabolicsNovo NordiskPharmaceuticalResearchSaxendaUSA

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

19-09-2014

The global burden of diabetes is growing fast with an astonishing 10% of global healthcare expense spent…

DenmarkDiabetesEuropeMexicoNovo NordiskPharmaceuticalResearchRyzodegTresibaXultophy

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

16-09-2014

Danish diabetes care giant Novo Nordisk announced positive new data from the BEGIN YOUNG 1 trial today,…

DiabetesNovo NordiskPharmaceuticalResearchTresiba

FDA advisory votes to approve Novo Nordisk diabetes drug for obesity

FDA advisory votes to approve Novo Nordisk diabetes drug for obesity

12-09-2014

There was good news for Danish diabetes care giant Novo Nordisk yesterday, when the US Food and drug…

liraglutideMetabolicsNovo NordiskPharmaceuticalRegulationSaxenda

The FDA publishes Novo Nordisk briefing documents ahead of Saxenda Advisory Committee meeting

The FDA publishes Novo Nordisk briefing documents ahead of Saxenda Advisory Committee meeting

09-09-2014

The US Food and Drug Administration has published briefing documents on Danish insulin giant Novo Nordisk’s…

Anti-diabetic drugsDiabetesliraglutideNovo NordiskPharmaceuticalRegulationTreatment of obesityUSA

Novo Nordisk pulls out of inflammatory disorders research

Novo Nordisk pulls out of inflammatory disorders research

02-09-2014

Danish diabetes care giant Novo Nordisk says it has decided to discontinue all its R&D activities within…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceutical

Mexico first country to launch Novo Nordisk’s Ryzodeg

Mexico first country to launch Novo Nordisk’s Ryzodeg

01-09-2014

Danish diabetes care giant Novo Nordisk today announced that Mexico has become the first country in the…

DiabetesMarkets & MarketingMexicoNovo NordiskPharmaceuticalRyzodeg

1 to 25 of 142 results

Back to top